Affiliation:
1. Institute of Antimicrobial Chemotherapy (Smolensk, Russia)
2. N.N. Burdenko National Medical Research Center of Neurosurgery (Moscow, Russia)
Abstract
Objective.
To analyse aggregated AST results for key microorganisms collected through the 2022 reports of chief specialists in clinical microbiology and antimicrobial resistance.
Materials and Methods.
The study included an analysis of the interpretation criteria used in the laboratories and an evaluation of the AST reports. Data were obtained from the clinical microbiology and antimicrobial resistance annual reporting system. Reports were analyzed using EUCAST guidelines for expected resistance phenotypes and expected susceptible phenotypes. Data processing and analysis were realized using the «R» programming language. The 95% CI for the percentages of inaccuracies/errors distributed by federal districts was calculated using the Wilson method.
Results.
A combination of several interpretation standards was used in 27.78% of laboratories, MUK 4.2.1890-04 was noted as one of the options in 57.6% of laboratories. Irrelevant standards of interpretation with a lag of 1 year or more were used in a significant number of cases. The highest percentage of errors/ inaccuracies by the type «expected resistance» was observed for A. baumannii – 14,06% (N = 9163), E. faecium – 8,05% (N = 3451) and S. pneumoniae – 6,18% (N = 2779). «Susceptibility categorization in the absence of interpretive breakpoints» was highest for S. aureus – 13.24% (N = 19784) and S. pneumoniae – 8.76% (N = 3942). Rare phenotype was determined in the highest percentage in relation to S. pneumoniae and antimicrobials: vancomycin – 54.04% and linezolid – 64.6%.
Conclusions.
The study revealed a significant number of errors/inaccuracies in the data reported. The use of irrelevant interpretation criteria, the exclusion of situations with rare phenotypes and expected resistance, may contribute to a significant increase in the likelihood of inappropriate antibacterial prescribing.
Publisher
Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),Epidemiology
Reference24 articles.
1. Murray C., Ikuta K., Sharara F., Swetschinski L., Aguilar G., Gray A., et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. DOI: 10.1016/S01406736(21)02724-0
2. Aslam B., Wang W., Arshad M., Khurshid M., Muzammil S., Rasool M., et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645-1658. DOI: 10.2147/IDR.S17386
3. Ventola C. The antibiotic resistance crisis: part 1: causes and threats. P.T. 2015;40(4):277-283. PMID: 25859123
4. Zhen X., Stalsby Lundborg C., Sun X., Zhu N., Gu S., Dong H. Economic burden of antibiotic resistance in China: a national level estimate for inpatients. Antimicrob Resist Infect Control. 2021;10(1):5. DOI: 10.1186/s13756020-00872-w
5. World Bank. Drug-Resistant Infections: a threat to our economic future. 2017. Available at: http://hdl.handle.net/10986/26707. Accessed May 2023.